Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (3 June 2026) authorised the medicine resmetirom (Rezdiffra) to treat adult patients with metabolic dysfunction-associated steatohepatitis (MASH).

Follow this news feed: